Efficacy of polyadenylic.polyuridylic acid in the treatment of chronic active hepatitis B

Baik Hahm Ki Baik Hahm; Hyub Han Kwang Hyub Han; Ho Kim Won Ho Kim; Soon Yim Dae Soon Yim; Yoon Chon Chae Yoon Chon; Myung Moon Young Myung Moon; Kyung Kang Jin Kyung Kang; Suh Park In Suh Park; Koo Youn Jung Koo Youn; Evelyne Deschamps de Paillette

doi:10.1016/0192-0561(94)90015-9

Efficacy of polyadenylic.polyuridylic acid in the treatment of chronic active hepatitis B

Baik Hahm Ki Baik Hahm, Hyub Han Kwang Hyub Han, Ho Kim Won Ho Kim, Soon Yim Dae Soon Yim, Yoon Chon Chae Yoon Chon, Myung Moon Young Myung Moon, Kyung Kang Jin Kyung Kang, Suh Park In Suh Park, Koo Youn Jung Koo Youn, Evelyne Deschamps de Paillette

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

In order to assess whether polyadenylic. polyuridylic acid [poly(A).poly(U)] can be used as a new therapeutic agent for the treatment of chronic hepatitis B, 19 patients with histologically proven chronic active hepatitis B were injected intravenously with 100-150 mg of poly(A).poly(U) weekly for six weeks. Changes in alanine aminotransferase (ALT) levels, 2′.5′-olidoadenylate synthetase (2.5′.5′-AS) activities and HBV markers were sequentially checked during and after treatments. Serum ALT levels were decreased gradually and 2′.5′-AS activities were significantly increased after initiation of poly(A).poly(U) injections. At the end of this trial (24th week) we have observed the normalizations of elevated ALT levels in 14 (73.7%), negative conversion of HBeAg in 11 (57.9%) and loss of HBV-DNA in 12 out of 19 patients (63.1%). Complete responses which had both normalization of ALT levels and negative conversion of HBeAg were noted in 11 patients (57.9%) and partial responses showing either normalization of ALT levels or negative conversion of HBeAg alone were in four out of 19 patients (21.1%). No notable adverse effects were observed during the treatments and follow-up period. It can be concluded that poly(A).poly(U) seems to be effective in the treatment of chronic active hepatitis B and has an advantage of being free of significant side effects.

Original language	English
Pages (from-to)	217-225
Number of pages	9
Journal	International Journal of Immunopharmacology
Volume	16
Issue number	3
DOIs	https://doi.org/10.1016/0192-0561(94)90015-9
Publication status	Published - 1994 Mar

Bibliographical note

Funding Information:
Acknowledgements -- This work was supported, partly, by the grant from Institut Henri Beaufour, Paris 7b, France. The authors would like to thank Professor Hyun-Sook Kim, Department of Clinical Pathology, Yonsei University for giving help in measuring HBV-DNA and Mr Eun-Sung Kim, Institute of Cheil Foods & Chemical's Inc., Research & Development Center, Korea, for mearuring 2'.5'-AS activities.

All Science Journal Classification (ASJC) codes

Immunology
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0192-0561(94)90015-9

Cite this

Ki Baik Hahm, B. H., Kwang Hyub Han, H. H., Won Ho Kim, H. K., Dae Soon Yim, S. Y., Chae Yoon Chon, Y. C., Young Myung Moon, M. M., Jin Kyung Kang, K. K., In Suh Park, S. P., Jung Koo Youn, K. Y., & de Paillette, E. D. (1994). Efficacy of polyadenylic.polyuridylic acid in the treatment of chronic active hepatitis B. International Journal of Immunopharmacology, 16(3), 217-225. https://doi.org/10.1016/0192-0561(94)90015-9

@article{6a45f937ebed40bb9ce307aab958e09b,

title = "Efficacy of polyadenylic.polyuridylic acid in the treatment of chronic active hepatitis B",

abstract = "In order to assess whether polyadenylic. polyuridylic acid [poly(A).poly(U)] can be used as a new therapeutic agent for the treatment of chronic hepatitis B, 19 patients with histologically proven chronic active hepatitis B were injected intravenously with 100-150 mg of poly(A).poly(U) weekly for six weeks. Changes in alanine aminotransferase (ALT) levels, 2′.5′-olidoadenylate synthetase (2.5′.5′-AS) activities and HBV markers were sequentially checked during and after treatments. Serum ALT levels were decreased gradually and 2′.5′-AS activities were significantly increased after initiation of poly(A).poly(U) injections. At the end of this trial (24th week) we have observed the normalizations of elevated ALT levels in 14 (73.7%), negative conversion of HBeAg in 11 (57.9%) and loss of HBV-DNA in 12 out of 19 patients (63.1%). Complete responses which had both normalization of ALT levels and negative conversion of HBeAg were noted in 11 patients (57.9%) and partial responses showing either normalization of ALT levels or negative conversion of HBeAg alone were in four out of 19 patients (21.1%). No notable adverse effects were observed during the treatments and follow-up period. It can be concluded that poly(A).poly(U) seems to be effective in the treatment of chronic active hepatitis B and has an advantage of being free of significant side effects.",

author = "{Ki Baik Hahm}, {Baik Hahm} and {Kwang Hyub Han}, {Hyub Han} and {Won Ho Kim}, {Ho Kim} and {Dae Soon Yim}, {Soon Yim} and {Chae Yoon Chon}, {Yoon Chon} and {Young Myung Moon}, {Myung Moon} and {Jin Kyung Kang}, {Kyung Kang} and {In Suh Park}, {Suh Park} and {Jung Koo Youn}, {Koo Youn} and {de Paillette}, {Evelyne Deschamps}",

note = "Funding Information: Acknowledgements -- This work was supported, partly, by the grant from Institut Henri Beaufour, Paris 7b, France. The authors would like to thank Professor Hyun-Sook Kim, Department of Clinical Pathology, Yonsei University for giving help in measuring HBV-DNA and Mr Eun-Sung Kim, Institute of Cheil Foods & Chemical's Inc., Research & Development Center, Korea, for mearuring 2'.5'-AS activities.",

year = "1994",

month = mar,

doi = "10.1016/0192-0561(94)90015-9",

language = "English",

volume = "16",

pages = "217--225",

journal = "International Journal of Immunopharmacology",

issn = "0192-0561",

publisher = "Elsevier",

number = "3",

}

Ki Baik Hahm, BH, Kwang Hyub Han, HH, Won Ho Kim, HK, Dae Soon Yim, SY, Chae Yoon Chon, YC, Young Myung Moon, MM, Jin Kyung Kang, KK, In Suh Park, SP, Jung Koo Youn, KY & de Paillette, ED 1994, 'Efficacy of polyadenylic.polyuridylic acid in the treatment of chronic active hepatitis B', International Journal of Immunopharmacology, vol. 16, no. 3, pp. 217-225. https://doi.org/10.1016/0192-0561(94)90015-9

TY - JOUR

T1 - Efficacy of polyadenylic.polyuridylic acid in the treatment of chronic active hepatitis B

AU - Ki Baik Hahm, Baik Hahm

AU - Kwang Hyub Han, Hyub Han

AU - Won Ho Kim, Ho Kim

AU - Dae Soon Yim, Soon Yim

AU - Chae Yoon Chon, Yoon Chon

AU - Young Myung Moon, Myung Moon

AU - Jin Kyung Kang, Kyung Kang

AU - In Suh Park, Suh Park

AU - Jung Koo Youn, Koo Youn

AU - de Paillette, Evelyne Deschamps

N1 - Funding Information: Acknowledgements -- This work was supported, partly, by the grant from Institut Henri Beaufour, Paris 7b, France. The authors would like to thank Professor Hyun-Sook Kim, Department of Clinical Pathology, Yonsei University for giving help in measuring HBV-DNA and Mr Eun-Sung Kim, Institute of Cheil Foods & Chemical's Inc., Research & Development Center, Korea, for mearuring 2'.5'-AS activities.

PY - 1994/3

Y1 - 1994/3

N2 - In order to assess whether polyadenylic. polyuridylic acid [poly(A).poly(U)] can be used as a new therapeutic agent for the treatment of chronic hepatitis B, 19 patients with histologically proven chronic active hepatitis B were injected intravenously with 100-150 mg of poly(A).poly(U) weekly for six weeks. Changes in alanine aminotransferase (ALT) levels, 2′.5′-olidoadenylate synthetase (2.5′.5′-AS) activities and HBV markers were sequentially checked during and after treatments. Serum ALT levels were decreased gradually and 2′.5′-AS activities were significantly increased after initiation of poly(A).poly(U) injections. At the end of this trial (24th week) we have observed the normalizations of elevated ALT levels in 14 (73.7%), negative conversion of HBeAg in 11 (57.9%) and loss of HBV-DNA in 12 out of 19 patients (63.1%). Complete responses which had both normalization of ALT levels and negative conversion of HBeAg were noted in 11 patients (57.9%) and partial responses showing either normalization of ALT levels or negative conversion of HBeAg alone were in four out of 19 patients (21.1%). No notable adverse effects were observed during the treatments and follow-up period. It can be concluded that poly(A).poly(U) seems to be effective in the treatment of chronic active hepatitis B and has an advantage of being free of significant side effects.

AB - In order to assess whether polyadenylic. polyuridylic acid [poly(A).poly(U)] can be used as a new therapeutic agent for the treatment of chronic hepatitis B, 19 patients with histologically proven chronic active hepatitis B were injected intravenously with 100-150 mg of poly(A).poly(U) weekly for six weeks. Changes in alanine aminotransferase (ALT) levels, 2′.5′-olidoadenylate synthetase (2.5′.5′-AS) activities and HBV markers were sequentially checked during and after treatments. Serum ALT levels were decreased gradually and 2′.5′-AS activities were significantly increased after initiation of poly(A).poly(U) injections. At the end of this trial (24th week) we have observed the normalizations of elevated ALT levels in 14 (73.7%), negative conversion of HBeAg in 11 (57.9%) and loss of HBV-DNA in 12 out of 19 patients (63.1%). Complete responses which had both normalization of ALT levels and negative conversion of HBeAg were noted in 11 patients (57.9%) and partial responses showing either normalization of ALT levels or negative conversion of HBeAg alone were in four out of 19 patients (21.1%). No notable adverse effects were observed during the treatments and follow-up period. It can be concluded that poly(A).poly(U) seems to be effective in the treatment of chronic active hepatitis B and has an advantage of being free of significant side effects.

UR - http://www.scopus.com/inward/record.url?scp=0028221511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028221511&partnerID=8YFLogxK

U2 - 10.1016/0192-0561(94)90015-9

DO - 10.1016/0192-0561(94)90015-9

M3 - Article

C2 - 8206687

AN - SCOPUS:0028221511

SN - 0192-0561

VL - 16

SP - 217

EP - 225

JO - International Journal of Immunopharmacology

JF - International Journal of Immunopharmacology

IS - 3

ER -

Efficacy of polyadenylic.polyuridylic acid in the treatment of chronic active hepatitis B

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this